x

¿Aún no esta registrado?

Crea tu cuenta. Registrate en Elsevier y obtendrás:

Registrarme ahora
España | Cambiar
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2013

1,881
© Thomson Reuters, Journal Citation Reports, 2013

Indexada en:

Index Current Contents/Clinical Medicine, JCR, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, CANCERLIT, SCOPUS

Índice SCImago

SCImago Journal & Country Rank
doi: 10.1016/S0213-005X(12)70071-X

Daptomicina en las infecciones por bacterias grampositivas en pacientes oncohematológicos y en receptores de trasplante

Daptomycin in Gram-positive bacterial infections in oncohematological patients and transplant recipients

Jordi Carratalà a, , Óscar Len b, Julián de la Torre-Cisneros c

a Servicio de Enfermedades Infecciosas, Hospital Universitari de Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, España
b Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d’Hebron-VHIR, Barcelona, España
c Unidad de Gestión Clínica de Enfermedades Infecciosas, Hospital Universitario Reina Sofía-IMIBIC, Universidad de Córdoba, Córdoba, España

Palabras Clave

Neutropenia. Trasplante de progenitores hematopoyéticos. Trasplante de órgano sólido. Bacterias grampositivas. Bacteriemia. Daptomicina.

Keywords

Neutropenia. Hematopoietic stem cell transplantation. Solid organ transplantation. Gram-positive bacteria. Bacteremia. Daptomycin.

Resumen

Las infecciones por bacterias grampositivas son una causa importante de morbilidad y mortalidad en los pacientes oncohematológicos y en los receptores de trasplante. Los estafilococos coagulasa negativa, Staphylococcus aureus, Enterococcus spp. y los estreptococos del grupo viridans son los organismos grampositivos aislados con mayor frecuencia. La resistencia antibiótica en estos organismos es un problema en aumento y supone un reto terapéutico. Daptomicina es un antibiótico con una rápida actividad bactericida, de amplio espectro frente a bacterias grampositivas, incluidas las cepas resistentes a otros fármacos. En este artículo se revisan algunos aspectos de las infecciones por organismos grampositivos en estos pacientes inmunodeprimidos y se analiza con detalle la experiencia con daptomicina en el tratamiento de tales infecciones.

Abstract

Gram-positive infections are a major cause of morbidity and mortality in oncohematological patients and transplant recipients. The most frequently isolated Gram-positive organisms are the coagulase-negative staphylococci, Staphylococcus aureus and Enterococcus spp., and viridans group streptococci. Antibiotic resistance in these organisms is increasing and poses a challenge to clinicians. Daptomycin is rapidly bactericidal against a broad spectrum of gram-positive bacteria, including strains resistant to other drugs. The present article reviews some aspects of Gram-positive infections in these immunocompromised patients and provides a detailed analysis of experience with daptomycin in the treatment of these infections.

El Texto completo solo esta disponible en PDF

Bibliografía

1.Cervera C, Moreno A. Infección bacteriana. En: Aguado J.M., Fotún J., Gavalda J., Pahissa A., Torre-Cisneros J., editors. Infeciones en pacientes trasplantados. Barcelona: Elsevier España S.L; 2009.
2.Snyder JJ, Israni AK, Peng Y, Zhang L, Simon TA, Kasiske BL. Rates of first infection following kidney transplant in the United States. Kidney Int. 2009; 75:317-26.
Medline
3.Kim YJ, Kim SI, Wie SH, Kim YR, Hur JA, Choi JY, et al. Infectious complications in living-donor liver transplant recipients: a 9-year single center experience. Transpl Infect Dis. 2008; 10:316-24.
Medline
4.Gavaldà J, Román A. Infección en el trasplante de pulmón. Enferm Infecc Microbiol Clin. 2007; 25:639-50.
Medline
5.Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with haematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003; 36:1103-10.
Medline
6.Yamasaki S, Heike Y, Mori S, Fukuda T, Maruyama D, Kato R, et al. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 patients of allogeneic hematopoietic stem cell transplantation with reduced-and conventional-intensity conditioning regimens. Transpl Infect Dis. 2008; 10:252-9.
Medline
7.Moreno A, Cervera C, Gavaldá J, Rovira M, De la Cámara R, Jarque I, et al. Bloodstrem infections among transplant recipients: results of a nationwide surveillance in Spain. Am J Transplant. 2007; 7:2579-86.
Medline
8.Cervera C, Moreno A. Infecciones en el paciente con trasplante renal y pancreático. Enferm Infecc Microbiol Clin. 2007; 25:345-55.
Medline
9.Fernández-Sabé N, Cervera C, López-Medrano F, Llano M, Sáez E, Len O, et al. Risk factors, clinical features, and outcomes of listeriosis in solid-organ transplant recipients: a matched case-control study. Clin Infect Dis. 2009; 49:1153-9.
Medline
10.Aguado JM, García-Reyne A, Lumbreras C. Infecciones en los pacientes trasplantados de hígado. Enferm Infecc Microbiol Clin. 2007; 25:401-10.
Medline
11.San-Juan R, Aguado JM, Lumbreras C, Fortún J, Len O, Muñoz P, et al. Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation. Liver Transpl. 2011; 17:896-904.
Medline
12.Aguilar-Guisado M, Gavaldà J, Ussetti P, Ramos A, Morales P, Blanes M, et al. Pneumonia after lung transplantation in the Resitra Cohort: a multicenter prospective study. Am J Transplant. 2007; 7:1989-96.
Medline
13.Torre-Cisneros J, Herrero C, Cañas E, Reguera JM, De la Mata M, Gómez-Bravo MA. Bacteremia after liver transplantation in the SAEI cohort: high mortality related with Staphylococcus aureus. Eur J Clin Microbiol Infect Dis. 2002; 21:385-8.
Medline
14.Garzoni C, The AST Infectious Diseases Community of Practice. Multiply resistant gram-positive bacteria methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus (MRSA, VISA, VRSA) in solid organ transplant recipients. Am J Tansplant. 2009; 9(Suppl 4):S41-9.
15.Santoro-Lopes G, De Gouvea EF, Monteiro RC, Branco RC, Rocco JR, Halpern M, et al. Colonization with methicillin-resistant Staphylococcus aureus after liver transplantation. Liver Transpl. 2005; 11:203-9.
Medline
16.Singh N, Squier C, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Impact of an aggressive infection control strategy on endemic Staphylococcus aureus infection in liver transplant recipients. Infect Control Hosp Epidemiol. 2006; 27:122-6.
Medline
17.Singh N, Paterson DL, Chang FY, Gayowski T, Squier C, Wagener MM, et al. Methicillin-resistant Staphylococcus aureus: the other emerging resistant grampositive coccus among liver transplant recipients. Clin Infect Dis. 2000; 30:322-7.
Medline
18.Bert F, Galdbart JO, Zarrouk V, Le Mée J, Durand F, Mentré F, et al. Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients. Clin Infect Dis. 2000; 31:1295-9.
Medline
19.Desai D, Desai N, Nightingale P, Elliott T, Neuberger J. Carriage of methicillinresistant Staphylococcus aureus is associated with an increased risk of infection after liver transplantation. Liver Transpl. 2003; 9:754-9.
Medline
20.Russell DL, Flood A, Zaroda TE, Acosta C, Riley MM, Busuttil RW, et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant. 2008; 8:1737-43.
Medline
21.Adeyemi OA, Qi C, Zembower TR, Ison MG, Grant TH, Hartigan BJ, et al. Invasive infections with community-associated methicillin-resistant Staphylococcus aureus after kidney transplantation. J Clin Microbiol. 2008; 46:2809-13.
Medline
22.Obed A, Schnitzbauer AA, Bein T, Lehn N, Linde HJ, Schlitt HJ. Fatal pneumonia caused by Panton-Valentine Leucocidine-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation. Transplantation. 2006; 81:121-4.
Medline
23.Bert F, Clarissou J, Durand F, Delefosse D, Chauvet C, Lefebrve P, et al. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptides intermediate Staphylococcus aureus in liver transplant recipients. J Clin Microbiol. 2003; 41:5147-52.
Medline
24.McNeil SA, Malani PN, Chenoweth CE, Fontana RJ, Magee JC, Punch JD, et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis. 2006; 42:195-203.
Medline
25.Muñoz P, The AST Infectious Diseases Community Practice. Multiply resistant gram-positive bacteria: vancomycin. resistant Enterococcus in solid organ transplantation. Am J Transplant. 2009; 9(Suppl 4):S50-6.
Medline
26.González-Barca E, Fernández-Sevilla A, Carratalà J, Grañena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis. 1996; 15:291-6.
Medline
27.Cordonnier C, Buzin A, Leverger G, Herbrecht R, Hunnault M, Leclercq R, et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis. 2003; 36:149-58.
Medline
28.Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis. 2004; 39:S25-31.
Medline
29.Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis. 1992; 14:1201-7.
Medline
30.Prabhuv RM, Piper KE, Litzow MR, Steckelberg JM, Patel R. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis. 2005; 24:832-8.
Medline
31.Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect. 2010; 138:1044-51.
Medline
32.Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001; 33:947-53.
Medline
33.Engelhard D, Elishoov H, Strauss N, Naparstek E, Nagler A, Simhon A, et al. Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. A 5-year prospective study. Transplantation. 1996; 61:430-4.
Medline
34.Costa SF, Barone AA, Miceli MH, Van der Heijden IM, Soares RE, Levin AS, et al. Colonization and molecular epidemiology of coagulase-negative staphylococcal bacteremia in cancer patients: a pilot study. Am J Infect Control. 2006; 34:36-40.
Medline
35.Tunkel AR, Sepkowitz KA. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis. 2002; 34:1524-9.
Medline
36.Marron A, Carratalà J, González-Barca E, Fernández-Sevilla A, Alcaide F, Gudiol F. Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer. Clin Infect Dis. 2000; 31:1126-30.
Medline
37.Carratalà J, Alcaide F, Fernández-Sevilla A, Corbella X, Liñares J, Gudiol F. Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer. Clin Infect Dis. 1995; 20:1169-73.
Medline
38.Marron A, Carratalà J, Alcaide F, Fernández-Sevilla A, Gudiol F. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. J Antimicrob Chemother. 2001; 47:87-91.
Medline
39.Huang WT, Chang LY, Hsueh PR, Lu CY, Shao PL, Huang FY, et al. Clinical features and complications of viridans streptococci bloodstream infection in pediatric hemato-oncology patients. J Microbiol Immunol Infect. 2007; 40:349-54.
Medline
40.Montecalvo MA, Horowitz H, Gedris C, Carbonaro C, Tenover FC, Issah A, et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother. 1994; 38:1363-7.
Medline
41.Marron A, Carratalà J, Ayats J, Fernández-Sevilla A, Domínguez MA, Liñares J, et al. Bacteriemia por enterococos resistentes a vancomicina en los pacientes neutropénicos con cáncer. Med Clin (Barc). 1998; 111:761-4.
42.Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer. 2011; 19:231-7.
Medline
43.González-Barca E, Carratalà J, Mykietiuk A, Fernández-Sevilla A, Gudiol F. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur J Clin Microbiol Infect Dis. 2001; 20:117-9.
Medline
44.Falcone M, Micozzi A, Pompeo ME, Baiocchi P, Fabi F, Penni A, et al. Methicilliresistant staphylococcal bacteremia in patients with hematologic malignancies: clinical and microbiological retrospective comparative analysis of S. haemolyticus, S. epidermidis, and S. aureus. J Chemother. 2004; 16:540-8.
Medline
45.Cuervo SI, Cortés JA, Sánchez R, Rodríguez JY, Silva E, Tibavizco D, et al. Risk factors for mortality caused by Staphylococcus aureus bacteremia in cancer patients. Enferm Infecc Microbiol Clin. 2010; 28:349-54.
Medline
46.Carratalà J, Rosón B, Fernández-Sevilla A, Alcaide F, Gudiol F. Bacteremic pneumonia in neutropenic patients with cancer. Causes, empirical antibiotic therapy, and outcome. Arch Intern Med. 1998; 158:868-72.
Medline
47.Carratalà J, Marron A, Fernández-Sevilla A, Liñares J, Gudiol F. Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer. Clin Infect Dis. 1997; 24:148-52.
Medline
48.Van der Lelie H, Leverstein-Van Hall M, Mertens M, Van Zaanen HCT, Van Oers RHJ, Thomas BLM, et al. Corynebacterium CDC group JK (Corynebacterium jeikeium) sepsis in haematological patients: a report of three cases and systematic literature review. Scand J Infect Dis. 1995; 27:581-4.
Medline
49.Jucglà A, Sais G, Carratalà J, Moreno A, Fernández-Sevilla A, Peyri J. A papular eruption secondary to infection with Corynebacterium jeikeium, with histopathological features mimicking botryomycosis. Br J Dermatol. 1995; 133:801-4.
Medline
50.Sader HS, Fritsche TR, Jones RN. Frequency of ocurrence and daptomycin susceptibility rates of gram-positive organisms causing bloodstream infections in cancer patients. J Chemother. 2008; 20:570-6.
Medline
51.Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infectious Diseases. 2007; 7:29.
Medline
52.Kratzer C, Rabitsch W, Hirschl AM, Graninger W, Presteri E. In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients. Eur J Haematol. 2007; 79:405-9.
Medline
53.Sader HS, Farrell DJ, Jones RN. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003–2009). J Chemother. 2011; 23:200-6.
Medline
54.Chang FY, Peacock JE, Musher DM, Triplett P, MacDonald BB, Mylotte JM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore). 2003; 82:333-9.
55.Commetta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003; 37:382-9.
Medline
56.Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analylis of two double-blind studies of patients with methicillinresistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003; 124:1789-97.
Medline
57.Jaksic B, Martinelli G, Pérez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006; 42:597-607.
Medline
58.Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011; 52:285-92.
Medline
59.Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006; 355:653-65.
Medline
60.Figueroa DA, Mangini E, Amodio-Groton M, Verdianos B, Melchert A, Fana C, et al. Safety of highdose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009; 49:177-80.
Medline
61.Mueller BA, Crompton JA, Donovan BJ, Yankalev S, Lamp KC. Safety of daptomycin in patients receiving hemodialysis. Pharmacotherapy. 2011; 31:665-72.
Medline
62.Barber GR, Lauretta J, Sáez R. A febrile neutropenic patient with Enterococcus gallinarum sepsis treated with daptomycin and gentamicin. Pharmacotherapy. 2007; 27:927-32.
Medline
63.Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect. 2007; 54:567-71.
Medline
64.Mergenhagen KA, Pasko MT. Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis. Ann Pharmacother. 2007; 41:1531-5.
Medline
65.Rolston KV, McConnell SA, Brown J, Lamp KC. Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry. Clin Adv Hematol Oncol. 2010; 8:249-56.
Medline
66.Chaftari AM, Hachem R, Mulanovich V, Chemaly RF, Adachi J, Jacobson K, et al. Efficacy and safety of daptomycin in the treatment of Gram-positive catheterrelated bloodstream infections in cancer patients. Int J Antimicrob Agents. 2010; 62:182-6.
67.Kraft S, Mackler E, Schlickman P, Welch K, Depestel DD. Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Support Care Cancer. 2011; 19:1969-74.
Medline
68.Kamboj M, Cohen N, Gilhuley K, Babady NE, Seo SK, Sepkowitz KA. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol. 2011; 32:391-4.
Medline
69.Vernadakis S, Saner FH, Rath PM, Kaiser GM, Mathe Z, Treckmann J, et al. Successful salvage therapy with daptomycin after linezolid and vancomycin failure in a liver transplant recipient with methicillin-resistant Staphylococcus aureus endocarditis. Transpl Infect Dis. 2009; 1:346-8.
70.Len O, Gavaldà J, Cervera C, Montejo M, Arnaiz A, Fernández-Sabé N, et al. Daptomycin in the treatment of Gram-positive cocci in solid organ transplantation. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Boston. 2010. September, 12–15, Abstract A1-045